Healthcare · Biotechnology
Price
$632.90
Market Cap
$65.2B
Employees
15,158
Beta
0.24
Avg Volume
963,506
CEO
Leonard S. Schleifer
Business Description
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
14.88
Stock Price: $632.90
EPS (Diluted): 43.07
EPS (Diluted): 43.07
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.58
Stock Price: $632.90
Total Equity: $31.26B
Shares: 108,600,000
Total Equity: $31.26B
Shares: 108,600,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
11.31
Market Cap: $65.20B
Total Debt: $1.99B
Cash: $3.12B
EBITDA: $5.82B
Total Debt: $1.99B
Cash: $3.12B
EBITDA: $5.82B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$80.3B
Market Cap: $65.20B
Total Debt: $1.99B
Cash: $3.12B
Total Debt: $1.99B
Cash: $3.12B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
85.4%
Gross Profit: $12.24B
Revenue: $14.34B
Revenue: $14.34B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
24.9%
Operating Income: $3.58B
Revenue: $14.34B
Revenue: $14.34B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
31.4%
Net Income: $4.50B
Revenue: $14.34B
Revenue: $14.34B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
14.3%
Net Income: $4.50B
Total Equity: $31.26B
Total Equity: $31.26B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
8.5%
Operating Income: $3.58B
Tax Rate: 13.9%
Equity: $31.26B
Total Debt: $1.99B
Cash: $3.12B
Tax Rate: 13.9%
Equity: $31.26B
Total Debt: $1.99B
Cash: $3.12B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
4.13
Current Assets: $18.02B
Current Liabilities: $4.37B
Current Liabilities: $4.37B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.06
Short-Term Debt: $0.00
Long-Term Debt: $1.99B
Total Debt: $1.99B
Total Equity: $31.26B
Long-Term Debt: $1.99B
Total Debt: $1.99B
Total Equity: $31.26B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$132.07
Revenue: $14.34B
Shares: 108,600,000
Shares: 108,600,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$287.82
Total Equity: $31.26B
Shares: 108,600,000
Shares: 108,600,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$37.57
Operating CF: $4.98B
CapEx: -$898.40M
Shares: 108,600,000
CapEx: -$898.40M
Shares: 108,600,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.5%
Last Dividend: N/A
Stock Price: $632.90
Stock Price: $632.90
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $4.50B
Net Income: $4.50B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares REGN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 4:42am (4h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Cost of Revenue | $2.7B | $1.7B | $2.2B | $2.0B | $2.1B |
| Gross Profit | $13.3B | $10.5B | $10.9B | $12.2B | $12.2B |
| Operating Expenses | $4.4B | $5.1B | $6.5B | $8.2B | $8.7B |
| Operating Income | $8.9B | $5.4B | $4.3B | $4.0B | $3.6B |
| Net Income | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B |
| EBITDA | $9.7B | $5.3B | $4.7B | $5.3B | $5.8B |
| EPS | $76.40 | $40.51 | $37.05 | $40.90 | $43.07 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 4:42am (4h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.9B | $3.1B | $2.7B | $2.5B | $3.1B |
| Total Current Assets | $14.0B | $15.9B | $19.5B | $18.7B | $18.0B |
| Total Assets | $25.4B | $29.2B | $33.1B | $37.8B | $40.6B |
| Current Liabilities | $3.9B | $3.1B | $3.4B | $3.9B | $4.4B |
| Long-Term Debt | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B |
| Total Liabilities | $6.7B | $6.6B | $7.1B | $8.4B | $9.3B |
| Total Equity | $18.8B | $22.7B | $26.0B | $29.4B | $31.3B |
| Retained Earnings | $19.0B | $23.3B | $27.3B | $31.7B | $35.8B |
Cash Flow (Annual)
Last updated: Jun 27, 2026 4:42am (4h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.1B | $5.0B | $4.6B | $4.4B | $5.0B |
| Capital Expenditure | -$551.9M | -$590.1M | -$926.4M | -$755.9M | -$898.4M |
| Free Cash Flow | $6.5B | $4.4B | $3.7B | $3.7B | $4.1B |
| Acquisitions (net) | $551.9M | -$230.3M | -$54.9M | -$16.5M | -$3.3M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$2.7B | -$2.5B | -$2.2B | -$3.6B | -$4.0B |
| Net Change in Cash | $690.8M | $221.3M | -$381.6M | -$248.8M | $634.7M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 4:42am (4h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$17.6B $16.1B – $19.2B
|
$18.9B $18.9B – $18.9B
|
$21.0B $19.5B – $22.6B
|
$21.5B $19.9B – $23.1B
|
| EBITDA |
$7.6B $7.0B – $8.3B
|
$8.2B $8.2B – $8.2B
|
$9.1B $8.5B – $9.8B
|
$9.3B $8.7B – $10.0B
|
| Net Income |
$5.1B $3.3B – $7.2B
|
$5.8B $5.4B – $8.0B
|
$7.8B $7.1B – $8.6B
|
$7.8B $7.0B – $8.5B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 4:42am (4h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -24.3% | +7.8% | +8.3% | +1.0% |
| Gross Profit Growth | -21.6% | +3.9% | +12.5% | +0.1% |
| Operating Income Growth | -39.8% | -19.3% | -8.2% | -10.3% |
| Net Income Growth | -46.3% | -8.9% | +11.6% | +2.1% |
| EBITDA Growth | -45.6% | -10.8% | +13.3% | +9.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:42am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 5.00 | $701.76 | $3,509 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 15.00 | $702.46 | $10,537 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 24.00 | $703.46 | $16,883 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 15.00 | $704.28 | $10,564 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 14.00 | $705.56 | $9,878 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 7.00 | $706.74 | $4,947 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 4.00 | $707.40 | $2,830 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 6.00 | $709.45 | $4,257 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 2.00 | $710.87 | $1,422 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 5.00 | $711.49 | $3,557 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 1.00 | $712.09 | $712 |
| 2026-05-01 | RYAN ARTHUR F | S-Sale | 2.00 | $714.13 | $1,428 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 1.00 | $771.32 | $771 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 3.00 | $772.76 | $2,318 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 8.00 | $773.59 | $6,189 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 8.00 | $774.58 | $6,197 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 14.00 | $775.58 | $10,858 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 13.00 | $776.62 | $10,096 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 9.00 | $777.42 | $6,997 |
| 2026-04-01 | RYAN ARTHUR F | S-Sale | 4.00 | $778.24 | $3,113 |
Dividend History (Last 20)
Last updated: Jun 27, 2026 4:42am (4h ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-20 | $0.94 | 2026-04-29 | 2026-05-20 | 2026-06-04 |
| 2026-02-20 | $0.94 | 2026-01-30 | 2026-02-20 | 2026-03-05 |
| 2025-11-20 | $0.88 | 2025-10-28 | 2025-11-20 | 2025-12-05 |
| 2025-08-18 | $0.88 | 2025-08-01 | 2025-08-18 | 2025-09-03 |
| 2025-05-20 | $0.88 | 2025-04-29 | 2025-05-20 | 2025-06-06 |
| 2025-02-20 | $0.88 | 2025-02-04 | 2025-02-20 | 2025-03-20 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for REGN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for REGN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30